Literature DB >> 24100447

The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG).

Sylvia Hartmann1, Dennis A Eichenauer, Annette Plütschow, Anja Mottok, Roshanak Bob, Karoline Koch, Heinz-Wolfram Bernd, Sergio Cogliatti, Michael Hummel, Alfred C Feller, German Ott, Peter Möller, Andreas Rosenwald, Harald Stein, Martin-Leo Hansmann, Andreas Engert, Wolfram Klapper.   

Abstract

Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) accounts for approximately 5% of all Hodgkin lymphoma cases. The aim of this study was to evaluate the prognostic implication of histopathologic NLPHL variants. Biopsies of 423 NLPHL patients treated within 9 prospective clinical trials performed by the German Hodgkin Study Group were classified as tumor cell-rich cases (n = 10), typical NLPHL (n = 308), or histopathologic variants (n = 105). Histopathologic variants were characterized by the presence of lymphoma cells outside the B-cell nodules or B-cell depletion of the microenvironment. Compared with typical NLPHL, histopathologic variants were associated with advanced disease (29.5% vs 14.6%, P = .0012) and a higher relapse rate (18.1% vs 6.5% at 5 years, P = .0009). Variant histology represented an independent prognostic factor (odds ratio = 2.955) in a multivariate model of progression/relapse. A prognostic score, including the risk factors variant histopathologic growth pattern, low serum albumin, and male gender, was derived from this model and allowed the definition of 3 distinct risk groups. NLPHL patients presenting with histopathologic variants have a poorer outcome compared with those showing typical histology. The newly developed prognostic score combining histologic and clinical features allows allocating NLPHL patients to defined risk groups.

Entities:  

Mesh:

Year:  2013        PMID: 24100447     DOI: 10.1182/blood-2013-07-515825

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  28 in total

1.  Ofatumumab in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: results of a phase II study from the German Hodgkin study group.

Authors:  D A Eichenauer; H Goergen; A Plütschow; D Wongso; K Behringer; S Kreissl; I Thielen; T Halbsguth; P J Bröckelmann; M Fuchs; B Böll; B von Tresckow; P Borchmann; A Engert
Journal:  Leukemia       Date:  2015-11-20       Impact factor: 11.528

2.  Highly recurrent mutations of SGK1, DUSP2 and JUNB in nodular lymphocyte predominant Hodgkin lymphoma.

Authors:  S Hartmann; B Schuhmacher; T Rausch; L Fuller; C Döring; M Weniger; A Lollies; C Weiser; L Thurner; B Rengstl; U Brunnberg; M Vornanen; M Pfreundschuh; V Benes; R Küppers; S Newrzela; M-L Hansmann
Journal:  Leukemia       Date:  2015-12-10       Impact factor: 11.528

Review 3.  Diagnosis of Hodgkin lymphoma in the modern era.

Authors:  Hao-Wei Wang; Jayalakshmi P Balakrishna; Stefania Pittaluga; Elaine S Jaffe
Journal:  Br J Haematol       Date:  2018-11-08       Impact factor: 6.998

Review 4.  Update on the classification of T-cell lymphomas, Hodgkin lymphomas, and histiocytic/dendritic cell neoplasms.

Authors:  Akira Satou; N Nora Bennani; Andrew L Feldman
Journal:  Expert Rev Hematol       Date:  2019-07-31       Impact factor: 2.929

Review 5.  Pediatric lymphomas and histiocytic disorders of childhood.

Authors:  Carl E Allen; Kara M Kelly; Catherine M Bollard
Journal:  Pediatr Clin North Am       Date:  2015-02       Impact factor: 3.278

6.  Variant histology, IgD and CD30 expression in low-risk pediatric nodular lymphocyte predominant Hodgkin lymphoma: A report from the Children's Oncology Group.

Authors:  Ramona Vesna Untanu; Jason Back; Burton Appel; Qinglin Pei; Lu Chen; Allen Buxton; David C Hodgson; Peter F Ehrlich; Louis S Constine; Cindy L Schwartz; Robert E Hutchison
Journal:  Pediatr Blood Cancer       Date:  2017-08-12       Impact factor: 3.167

Review 7.  [Update on nodular lymphocyte predominant Hodgkin's lymphoma and related lesions].

Authors:  S Hartmann; M-L Hansmann
Journal:  Pathologe       Date:  2017-02       Impact factor: 1.011

8.  [Treatment of low-risk pediatric lymphocyte-predominant Hodgkin lymphoma].

Authors:  Georg Mann; Wolfgang Holter
Journal:  Strahlenther Onkol       Date:  2016-11       Impact factor: 3.621

9.  Nodular lymphocyte predominant Hodgkin lymphoma: a Lymphoma Study Association retrospective study.

Authors:  Julien Lazarovici; Peggy Dartigues; Pauline Brice; Lucie Obéric; Isabelle Gaillard; Mathilde Hunault-Berger; Florence Broussais-Guillaumot; Emmanuel Gyan; Serge Bologna; Emmanuelle Nicolas-Virelizier; Mohamed Touati; Olivier Casasnovas; Richard Delarue; Frédérique Orsini-Piocelle; Aspasia Stamatoullas; Jean Gabarre; Luc-Matthieu Fornecker; Thomas Gastinne; Fréderic Peyrade; Virginie Roland; Emmanuel Bachy; Marc André; Nicolas Mounier; Christophe Fermé
Journal:  Haematologica       Date:  2015-10-01       Impact factor: 9.941

10.  [Nodular lymphocyte-dominant Hodgkin's lymphoma : LP cells show recurrent mutations in DUSP2, SGK1 and JUNB].

Authors:  S Hartmann
Journal:  Pathologe       Date:  2017-11       Impact factor: 1.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.